PMC:7195088 / 19867-20271 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"668","span":{"begin":254,"end":262},"obj":"Species"},{"id":"789","span":{"begin":175,"end":185},"obj":"Chemical"},{"id":"790","span":{"begin":203,"end":222},"obj":"Chemical"},{"id":"930","span":{"begin":30,"end":35},"obj":"Disease"},{"id":"931","span":{"begin":105,"end":122},"obj":"Disease"},{"id":"932","span":{"begin":287,"end":295},"obj":"Disease"},{"id":"933","span":{"begin":375,"end":384},"obj":"Disease"}],"attributes":[{"id":"A668","pred":"tao:has_database_id","subj":"668","obj":"Tax:9606"},{"id":"A789","pred":"tao:has_database_id","subj":"789","obj":"MESH:D003078"},{"id":"A790","pred":"tao:has_database_id","subj":"790","obj":"MESH:C558899"},{"id":"A930","pred":"tao:has_database_id","subj":"930","obj":"MESH:D005334"},{"id":"A931","pred":"tao:has_database_id","subj":"931","obj":"MESH:D011014"},{"id":"A932","pred":"tao:has_database_id","subj":"932","obj":"MESH:C000657245"},{"id":"A933","pred":"tao:has_database_id","subj":"933","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":105,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T11","span":{"begin":105,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":30,"end":35},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T97","span":{"begin":110,"end":122},"obj":"Disease"},{"id":"T98","span":{"begin":287,"end":295},"obj":"Disease"}],"attributes":[{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T99","span":{"begin":27,"end":28},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T100","span":{"begin":105,"end":109},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T101","span":{"begin":105,"end":109},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T102","span":{"begin":302,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T203","span":{"begin":175,"end":185},"obj":"Chemical"},{"id":"T204","span":{"begin":203,"end":222},"obj":"Chemical"},{"id":"T205","span":{"begin":203,"end":212},"obj":"Chemical"},{"id":"T206","span":{"begin":213,"end":222},"obj":"Chemical"},{"id":"T207","span":{"begin":302,"end":307},"obj":"Chemical"}],"attributes":[{"id":"A203","pred":"chebi_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/CHEBI_23359"},{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4","span":{"begin":110,"end":122},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T138","span":{"begin":159,"end":296},"obj":"Sentence"},{"id":"T139","span":{"begin":297,"end":346},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"negative swabs at day 14; (b) fever to normal temperature in days (follow-up 14 days); (c) resolution of lung inflammation in CT or X-ray (follow-up 30 days).\n• Comparison of colchicine (with or without lopinavir/ritonavir) vs. local standard of care in patients with moderate to severe COVID-19. Open-label RCT (NCT04328480, not yet recruiting). Primary endpoint: all-cause mortality (follow-up 30 days)"}